{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-350425","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2026-08-14T11:50:16+00:00","discovered_at":"2026-08-14T11:55:02.900964+00:00","generated_at":"2026-08-14T11:55:25.181918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TuHURA Q2 2026: cash $1.0M, R&D up to $6.6M, $50M credit facility extends runway to 2028","bullets":["Cash and equivalents $1.0M at June 30, 2026; $5.7M drawn on $50M Parkview credit facility to date.","R&D expenses $6.6M in Q2 2026 vs $4.9M in Q2 2025; G&A $2.1M vs $1.9M.","Net operating cash outflow -$13.0M for H1 2026 vs -$10.9M in H1 2025; financing inflows $10.6M.","Filed IND for TBS-2025 VISTA antibody in AML; expect Phase 1b/2 initiation 2H 2026 and orphan drug designations.","$50M credit facility from largest shareholder at 12% interest, maturity 2031, extends cash runway into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-350425","json":"https://secwatch.observer/filing/0001193125-26-350425.json","markdown":"https://secwatch.observer/filing/0001193125-26-350425.md","text":"https://secwatch.observer/filing/0001193125-26-350425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/0001193125-26-350425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T11:55:25.181918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}